{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:44:32Z","timestamp":1769813072675,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec><jats:label\/><jats:p>Candidates for onabotulinumtoxinA are generally patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) whose disease is inadequately controlled with behavioral therapy and oral medication. All patients must be willing and able to perform clean intermittent catheterization (CIC). Before the decision to administer onabotulinumtoxinA is made, the clinician should provide counseling to the patient regarding the agent's indications, proposed benefits, risks, and mode of administration. The patient should be aware that onabotulinumtoxinA takes effect after approximately 1\u20132 weeks and usually lasts for 4\u201310 months, after which repeat injections will be necessary to maintain effect. Patient preparation may include pre\u2010treatment antibiotics and withdrawal of antiplatelet therapy or anticoagulants. Preparation of the product involves reconstitution in sterile saline and dilution according to the planned dose. Local anesthesia (e.g., bladder instillation of lidocaine) is usually administered, although general anesthesia may be used in certain cases. The injections are performed using a flexible or rigid cystoscope, and the procedure takes approximately 15\u2009min. The initial follow\u2010up visit occurs within 7\u201314 days, when evidence of adverse effects, including urinary retention, can be evaluated. Repeat injections can be scheduled as needed, but not sooner than 3 months. Currently, the total dose of onabotulinumtoxinA should not exceed 360\u2009U in a 3\u2010month period for all indications, including those outside the urinary tract (i.e., cosmetic, ophthalmologic, etc.). Overall, onabotulinumtoxinA is effective, generally well tolerated, safe, and is relatively simple to provide. <jats:italic>Neurourol. Urodynam. 33:S32\u2013S37, 2014<\/jats:italic>. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.22637","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T15:48:02Z","timestamp":1404834482000},"source":"Crossref","is-referenced-by-count":24,"title":["Chapter 6: Practical aspects of administration of onabotulinumtoxinA"],"prefix":"10.1002","volume":"33","author":[{"given":"Eric","family":"Rovner","sequence":"first","affiliation":[{"name":"Department of Urology Medical University of South Carolina Charleston South Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.04.001"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.12.022"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.033"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.079"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.09.023"},{"key":"e_1_2_10_9_1","unstructured":"PannekJ St\u00f6hrerM BlokB et al.EAU guidelines on neurogenic lower urinary tract dysfunction.2011. Available at:http:\/\/www.uroweb.org\/gls\/pdf\/17_Neurogenic%20LUTS.pdf."},{"key":"e_1_2_10_10_1","unstructured":"LucasMG BoschRJ CruzF et al.EAU guidelines on urinary incontinence. Available at:www.uroweb.org\/gls\/pdf\/18_Urinary_Incontinence_LR.pdf."},{"key":"e_1_2_10_11_1","volume-title":"Botox 100 unit summary of product characteristics","author":"Allergan Pharmaceuticals","year":"2013"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.021"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.028"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21054"},{"key":"e_1_2_10_15_1","first-page":"3291","article-title":"Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone\u2010sparing injection","volume":"13","author":"Lucioni A","year":"2006","journal-title":"Can J Urol"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.02.2721"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2012.11.010"},{"key":"e_1_2_10_18_1","volume-title":"Botox prescribing information","author":"Allergan, Inc","year":"2013"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22637","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.22637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T16:39:48Z","timestamp":1696005588000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.22637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":17,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1002\/nau.22637"],"URL":"https:\/\/doi.org\/10.1002\/nau.22637","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}